Literature DB >> 11062061

Effect of alpha-1 antitrypsin Portland variant (alpha 1-PDX) on HIV-1 replication.

B Bahbouhi1, M Bendjennat, D Guétard, N G Seidah, E Bahraoui.   

Abstract

The present work investigated the potential role of alpha-1 antitrypsin Portland variant (alpha 1-PDX), a bioengineered serine proteinase inhibitor (serpin), in the interference with the viral replication of HIV-1, induction of syncytia and maturation of envelope glycoprotein gp160 to gp120 and gp41. A Jurkat lymphoid cell line transfected with a plasmid containing the alpha 1-PDX cDNA (J-PDX) and expressing the protein in a stable manner was infected with HIV-1(Lai). Controls were Jurkat cells transfected with the same vector pcDNA3 without the cDNA insert (J-pcDNA3). The results showed that viral replication of HIV-1 was significantly inhibited with a delay in replication kinetics in J-PDX cells as compared with J-pcDNA3 cells. In addition, a comparison of the infectious capacity of viruses produced in the presence and absence of alpha 1-PDX revealed that this capacity differed. It was found that alpha 1-PDX exerts its effect by interfering with the formation of syncytia between J-PDX cells infected with gp160 recombinant vaccinia virus, or after infection by HIV-1 and co-culture with uninfected Molt-4 cells. In contrast, when the same experiments were performed with J-pcDNA3 cells, a large number of syncytia was obtained. Analysis of viral proteins by Western blotting and densitometry showed that the inhibition of the cytopathic effect of HIV-1 and viral replication was correlated with the capacity of alpha 1-PDX to interfere with the maturation of gp160 to gp120 and gp41.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062061      PMCID: PMC1221435     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  47 in total

1.  Occurrence of an HIV-1 gp160 endoproteolytic activity in low-density vesicles and evidence for a distinct density distribution from endogenously expressed furin and PC7/LPC convertases.

Authors:  S Wouters; E Decroly; M Vandenbranden; D Shober; R Fuchs; V Morel; M Leruth; N G Seidah; P J Courtoy; J M Ruysschaert
Journal:  FEBS Lett       Date:  1999-07-30       Impact factor: 4.124

2.  A rapid and simple colorimetric test for the study of anti-HIV agents.

Authors:  O Schwartz; Y Henin; V Marechal; L Montagnier
Journal:  AIDS Res Hum Retroviruses       Date:  1988-12       Impact factor: 2.205

3.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

4.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

5.  Trypsin action on the growth of Sendai virus in tissue culture cells. 3. Structural difference of Sendai viruses grown in eggs and tissue culture cells.

Authors:  M Homma; M Ouchi
Journal:  J Virol       Date:  1973-12       Impact factor: 5.103

Review 6.  Human plasma proteinase inhibitors.

Authors:  J Travis; G S Salvesen
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

7.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.

Authors:  J M McCune; L B Rabin; M B Feinberg; M Lieberman; J C Kosek; G R Reyes; I L Weissman
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

10.  Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis.

Authors:  E Fenouillet; B Clerget-Raslain; J C Gluckman; D Guétard; L Montagnier; E Bahraoui
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Authors:  Benjamin M Scott; William P Sheffield
Journal:  Protein Sci       Date:  2019-12-09       Impact factor: 6.725

2.  Replication of HIV-1 viruses in the presence of the Portland alpha1-antitrypsin variant (alpha1-PDX) inhibitor.

Authors:  B Bahbouhi; N G Seidah; E Bahraoui
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

Review 3.  Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular Complications.

Authors:  Yi Ming; Liu Qiang
Journal:  SN Compr Clin Med       Date:  2020-07-11

4.  α₁-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α.

Authors:  Angelia D Lockett; Samuel Kimani; Godfrey Ddungu; Sabine Wrenger; Rubin M Tuder; Sabina M Janciauskiene; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

5.  Effects of L- and D-REKR amino acid-containing peptides on HIV and SIV envelope glycoprotein precursor maturation and HIV and SIV replication.

Authors:  Bouchaib Bahbouhi; Nathalie Chazal; Nabil Georges Seidah; Cristina Chiva; Marcelo Kogan; Fernando Albericio; Ernest Giralt; Elmostafa Bahraoui
Journal:  Biochem J       Date:  2002-09-15       Impact factor: 3.857

Review 6.  Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy.

Authors:  Abdel-Majid Khatib; Géraldine Siegfried; Michel Chrétien; Peter Metrakos; Nabil G Seidah
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

7.  Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry.

Authors:  Olfa Mzoughi; Meritxell Teixido; Rémi Planès; Manutea Serrero; Ibtissem Hamimed; Esther Zurita; Miguel Moreno; Giovana Granados; Faouzi Lakhdar-Ghazal; Lbachir BenMohamed; Ernest Giralt; Elmostafa Bahraoui
Journal:  Biosci Rep       Date:  2019-09-24       Impact factor: 3.840

8.  Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants.

Authors:  Anna Maisa; Ute Ströher; Hans-Dieter Klenk; Wolfgang Garten; Thomas Strecker
Journal:  PLoS Negl Trop Dis       Date:  2009-06-02

9.  A fluorogenic peptide containing the processing site of human SARS corona virus S-protein: kinetic evaluation and NMR structure elucidation.

Authors:  Ajoy Basak; Abhijit Mitra; Sarmistha Basak; Carolyn Pasko; Michel Chrétien; Pamela Seaton
Journal:  Chembiochem       Date:  2007-06-18       Impact factor: 3.164

10.  Potential Use of Alpha-1 Anti-trypsin in the Covid-19 Treatment.

Authors:  Fernanda Martini; Monica De Mattei; Carlo Contini; Mauro G Tognon
Journal:  Front Cell Dev Biol       Date:  2020-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.